Published in Vaccine Weekly, May 7th, 2003
According to recent research from France, "A collaborative study was organized by the European Directorate For the Quality of Medicines (EDQM) to assess the suitability of a candidate mouse antiserum as a European Pharmacopoeia Biological reference preparation (BRP) for acellular pertussis vaccine potency testing."
"The candidate antiserum was obtained by immunizing mice with a five-component acellular pertussis vaccine: pertussis toxin (PT), filamentous hemagglutinin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-05-07)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.